
Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.
Table of Contents
almost 24 years ago
Keep Your Pinstripes Verticalalmost 24 years ago
Resolutionsalmost 24 years ago
When Will the Bubble Burst?almost 24 years ago
Biogen's Big Picturealmost 24 years ago
A New Game Plan for Pharma HR





